Synaffix Is A Biotechnology Company Based In The Netherlandsfocused On Developing Antibody Drug Conjugatesadcs Bispecific Antibodiesand Targeted Therapeuticsfounded In 2010The Company Was Acquired By Lonza In June 2023Which Enhances Its Ability To Deliver Innovative Therapiesparticularly In Oncology The Company Operates A Technology Out Licensing Modelproviding Partners With Proprietary Adc And Bispecific Antibody Platformskey Features Include Site Specific Conjugation For Precise Payload Attachmenta Range Of Payload Types Such As Camptothecin And Maytansineand The Toxsynalinker Payload Systems Designed To Optimize Drug Deliverysynaffix Collaborates With Biopharmaceutical Companies Through Commercial Licensing Agreements And Has A Strong Intellectual Property Portfolio With 44 Patents Covering Various Biotechnology Innovationsits Mission Is To Advance Targeted Therapies That Maximize Efficacy While Minimizing Off Target Toxicity
No conferences found for this company.
| Company Name | Synaffix Bv |
| Country |
Netherlands
|
| Address | N/A |
| Telephone | N/A |
| N/A |
